Literature DB >> 15150129

ECL-cell derived gastric cancer in male cotton rats dosed with the H2-blocker loxtidine.

Reidar Fossmark1, Tom C Martinsen, Karin E Bakkelund, Shiro Kawase, Helge L Waldum.   

Abstract

Spontaneously hypergastrinemic cotton rats (Sigmodon hispidus) develop tumors that have the phenotype of an adenocarcinoma but most likely originate from the enterochromaffin-like (ECL) cells. Among inbred animals approximately 50% of the females, but <1% of males develop spontaneous gastric carcinomas. Gastrin is the principle carcinogen in this model, as >4 months of hypergastrinemia results in carcinoma, but a gastrin receptor antagonist prevents carcinomas. Carcinomas can also be induced by partial corpectomy. In the present study, the insurmountable H2-receptor antagonist loxtidine (200 mg/kg/day) was given to male cotton rats for 6 months. The loxtidine-dosed animals developed hypergastrinemia, whereas control animals remained normogastrinemic. At termination, 4 of 5 cotton rats had cancer located to the oxyntic mucosa, whereas 1 animal had dysplasia. The gastric mucosa of all of the control animals was normal. In the dysplastic mucosa of loxtidine-dosed animals there was a marked increase in chromogranin A-positive cells, where numerous groups of cells also stained positive with the Sevier-Munger technique. In areas of high proliferation and cancer there were also histidine decarboxylase, chromogranin A, and Sevier-Munger-positive cells, altogether indicating an ECL cell origin of the tumors. This represents an interesting animal model where ECL cell-derived gastric cancer can be induced by pharmacological acid inhibition in 6 months.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150129     DOI: 10.1158/0008-5472.CAN-03-3647

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Antiulcer drugs and gastric cancer.

Authors:  Helge L Waldum; Bjørn Gustafsson; Reidar Fossmark; Gunnar Qvigstad
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 2.  Gastric cancer: animal studies on the risk of hypoacidity and hypergastrinemia.

Authors:  Reidar Fossmark; Gunnar Qvigstad; Helge-L Waldum
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

3.  Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

Authors:  Irvin M Modlin; Steven F Moss; Daniel C Chung; Robert T Jensen; Elizabeth Snyderwine
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

4.  Comparison of PCR-based detection of chromogranin A mRNA with traditional histological lymph node staging of small intestinal neuroendocrine neoplasia.

Authors:  Ben Lawrence; Barton Kenney; Bernhard Svejda; Simon Schimmack; Daniele Alaimo; Andrea Barbieri; Jaroslaw Jedrych; Mark Kidd; Irvin Modlin
Journal:  BMC Res Notes       Date:  2012-06-21

5.  Gastric carcinomas localized to the cardia.

Authors:  Karin E Bakkelund; Ivar S Nordrum; Reidar Fossmark; Helge L Waldum
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

Review 6.  Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.

Authors:  Kenta Kawasaki; Masayuki Fujii; Toshiro Sato
Journal:  Dis Model Mech       Date:  2018-02-26       Impact factor: 5.758

Review 7.  Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility.

Authors:  Reidar Fossmark; Tom C Martinsen; Helge L Waldum
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

Review 8.  Towards Understanding of Gastric Cancer Based upon Physiological Role of Gastrin and ECL Cells.

Authors:  Helge Waldum; Patricia Mjønes
Journal:  Cancers (Basel)       Date:  2020-11-22       Impact factor: 6.639

9.  Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis.

Authors:  Li-Dong Zu; Xing-Chun Peng; Zhi Zeng; Jing-Long Wang; Li-Li Meng; Wei-Wei Shen; Chun-Ting Hu; Ye Yang; Guo-Hui Fu
Journal:  J Exp Clin Cancer Res       Date:  2018-06-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.